Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

AI Briefing

• – Aura Biosciences reports strong financial results, accelerates Phase 3 enrollment for CoMpass, and provides top line data guidance for 2H 2027.
• – Fourth quarter 2025 financial results show significant progress, with increased revenue and improved profitability.
• – Full year 2025 financial results demonstrate business growth and positioning for future success.